Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel …

AF Águeda, S Monti, RA Luqmani, F Buttgereit… - RMD open, 2019 - rmdopen.bmj.com
Objective To collect available evidence on management of large vessel vasculitis to inform
the 2018 update of the EULAR management recommendations. Methods Two independent …

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

B Hellmich, A Agueda, S Monti, F Buttgereit… - Annals of the …, 2020 - ard.bmj.com
Background Since the publication of the European League Against Rheumatism (EULAR)
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …

Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis

L Barra, G Yang, C Pagnoux, TCV Network - Autoimmunity reviews, 2018 - Elsevier
Abstract Background Takayasu's Arteritis (TAK) affects mostly young women and causes
significant morbidity. Most patients are refractory to glucocorticoids (GC) or relapse when GC …

Patient-reported outcome measures in Takayasu arteritis: a systematic review and meta-analysis

DP Misra, U Rathore, P Patro, V Agarwal… - Rheumatology and …, 2021 - Springer
Introduction We conducted a systematic review of patient-reported outcome measures
(PROMs) regarding quality of life, disability, mood abnormalities (anxiety, depression) …

Update on Takayasu's arteritis

F Alibaz-Oner, H Direskeneli - La Presse Médicale, 2015 - Elsevier
Takayasu arteritis (TAK) is a rare, chronic large-vessel vasculitis (LVV) that predominantly
affects aorta, its major branches and the pulmonary arteries. Recent advances in the …

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

B Grygiel‐Górniak, N Limphaibool… - Psychiatry and …, 2019 - Wiley Online Library
Research in the past two decades has revolutionized our understanding of depressive
illnesses. Proinflammatory cytokines have become a point of interest in the interconnecting …

Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016

AG Sreih, F Alibaz-Oner, TA Kermani… - The Journal of …, 2017 - jrheum.org
Objective. Among the challenges in conducting clinical trials in large-vessel vasculitis (LVV),
including both giant cell arteritis (GCA) and Takayasu arteritis (TA), is the lack of …

[PDF][PDF] S2K-Leitlinie: management der Großgefäßvaskulitiden

JH Schirmer, PM Aries, K Balzer, P Berlit, TA Bley… - Z Rheumatol, 2020 - academia.edu
Die Leitlinie wurde unter Berücksichtigung anderer zu diesem Thema publizierter Leitlinien
wie den aktualisierten Empfehlungen der European League Against Rheumatism (EULAR) …

Autoimmune encephalopathy for psychiatrists: when to suspect autoimmunity and what to do next

M Oldham - Psychosomatics, 2017 - Elsevier
Objective To provide a critical review of autoimmune encephalopathy—broadly defined as
neuropsychiatric features directly related to an autoimmune process—relevant for …

Outcome measures in large vessel vasculitis: relationship between patient‐, physician‐, imaging‐, and laboratory‐based assessments

CA Rimland, KA Quinn, JS Rosenblum… - Arthritis care & …, 2020 - Wiley Online Library
Objective To assess the relationship between measures of disease assessment in patients
with large vessel vasculitis. Methods Patients with giant cell arteritis (GCA) or Takayasu …